These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 7272500

  • 1. A rapid assay for evaluation of iron-chelating agents in rats.
    Pippard MJ, Johnson DK, Finch CA.
    Blood; 1981 Oct; 58(4):685-92. PubMed ID: 7272500
    [Abstract] [Full Text] [Related]

  • 2. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture.
    Hershko C, Konijn AM, Nick HP, Breuer W, Cabantchik ZI, Link G.
    Blood; 2001 Feb 15; 97(4):1115-22. PubMed ID: 11159545
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness of oral iron chelators assayed in the rat.
    Kim BK, Huebers HA, Finch CA.
    Am J Hematol; 1987 Mar 15; 24(3):277-84. PubMed ID: 3826055
    [Abstract] [Full Text] [Related]

  • 4. Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.
    Kontoghiorghes GJ, Sheppard L, Hoffbrand AV, Charalambous J, Tikerpae J, Pippard MJ.
    J Clin Pathol; 1987 Apr 15; 40(4):404-8. PubMed ID: 3584483
    [Abstract] [Full Text] [Related]

  • 5. Hepatocyte iron kinetics in the rat explored with an iron chelator.
    Pippard MJ, Johnson DK, Finch CA.
    Br J Haematol; 1982 Oct 15; 52(2):211-24. PubMed ID: 7126464
    [Abstract] [Full Text] [Related]

  • 6. Orally effective iron chelators for the treatment of iron overload disease: the case for a further look at pyridoxal isonicotinoyl hydrazone and its analogs.
    Richardson DR, Ponka P.
    J Lab Clin Med; 1998 Oct 15; 132(4):351-2. PubMed ID: 9794707
    [No Abstract] [Full Text] [Related]

  • 7. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells.
    Link G, Ponka P, Konijn AM, Breuer W, Cabantchik ZI, Hershko C.
    Blood; 2003 May 15; 101(10):4172-9. PubMed ID: 12511418
    [Abstract] [Full Text] [Related]

  • 8. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone.
    Cikrt M, Ponka P, Necas E, Neuwirt J.
    Br J Haematol; 1980 Jun 15; 45(2):275-83. PubMed ID: 7437326
    [Abstract] [Full Text] [Related]

  • 9. Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture.
    Baker E, Vitolo ML, Webb J.
    Biochem Pharmacol; 1985 Sep 01; 34(17):3011-7. PubMed ID: 4038321
    [Abstract] [Full Text] [Related]

  • 10. IRC011, a new synthetic chelator with selective interaction with catabolic red blood cell iron: evaluation in hypertransfused rats with hepatocellular and reticuloendothelial radioiron probes and in iron-loaded rat heart cells in culture.
    Rivkin G, Link G, Simhon E, Cyjon RL, Klein JY, Hershko C.
    Blood; 1997 Nov 15; 90(10):4180-7. PubMed ID: 9354689
    [Abstract] [Full Text] [Related]

  • 11. Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal.
    Hershko C, Avramovici-Grisaru S, Link G, Gelfand L, Sarel S.
    J Lab Clin Med; 1981 Jul 15; 98(1):99-108. PubMed ID: 7252329
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic potential of iron chelators in cancer therapy.
    Richardson DR.
    Adv Exp Med Biol; 2002 Jul 15; 509():231-49. PubMed ID: 12572997
    [Abstract] [Full Text] [Related]

  • 13. Origin and fate of iron mobilized by the 3-hydroxypyridin-4-one oral chelators: studies in hypertransfused rats by selective radioiron probes of reticuloendothelial and hepatocellular iron stores.
    Zevin S, Link G, Grady RW, Hider RC, Peter HH, Hershko C.
    Blood; 1992 Jan 01; 79(1):248-53. PubMed ID: 1728313
    [Abstract] [Full Text] [Related]

  • 14. Development and evaluation of the improved iron chelating agents EHPG, HBED and their dimethyl esters.
    Hershko C, Grady RW, Link G.
    Haematologia (Budap); 1984 Jan 01; 17(1):25-33. PubMed ID: 6427069
    [Abstract] [Full Text] [Related]

  • 15. In vivo iron mobilisation evaluation of hydroxypyridinones in 59Fe-ferritin-loaded rat model.
    Liu ZD, Lu SL, Hider RC.
    Biochem Pharmacol; 1999 Mar 01; 57(5):559-66. PubMed ID: 9952320
    [Abstract] [Full Text] [Related]

  • 16. Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease.
    Richardson DR, Ponka P.
    J Lab Clin Med; 1998 Apr 01; 131(4):306-15. PubMed ID: 9579383
    [Abstract] [Full Text] [Related]

  • 17. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone.
    Richardson DR, Milnes K.
    Blood; 1997 Apr 15; 89(8):3025-38. PubMed ID: 9108424
    [Abstract] [Full Text] [Related]

  • 18. The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis.
    Richardson DR, Ponka P.
    J Lab Clin Med; 1994 Nov 15; 124(5):660-71. PubMed ID: 7964124
    [Abstract] [Full Text] [Related]

  • 19. Biliary iron excretion in rats following treatment with analogs of pyridoxal isonicotinoyl hydrazone.
    Bláha K, Cikrt M, Nerudová J, Ponka HF.
    Blood; 1998 Jun 01; 91(11):4368-72. PubMed ID: 9596686
    [Abstract] [Full Text] [Related]

  • 20. Mobilization of iron from neoplastic cells by some iron chelators is an energy-dependent process.
    Richardson DR.
    Biochim Biophys Acta; 1997 May 16; 1320(1):45-57. PubMed ID: 9186779
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.